12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BMN-701: Phase I/II data

Data from 16 evaluable patients in the highest dose cohort of the open-label, international Phase I/II POM-001 trial showed that 3 patients receiving 20 mg/kg BMN-701 every 2 weeks achieved a >75 meter improvement in 6MWT distance from baseline to week 24. The mean change from baseline to week 24 in 6MWT distance for all 16 patients was 22.3 meters. Compared to baseline at...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >